TABLE 1.
A total of 107 patients with a concurrent EGFR mutation and ALK rearrangement have been documented, and their clinical features and treatment outcomes are listed.
| Investigator | Time | Patients (n) | Age (years) | Sex | Race | Smoking history | Histologic type | TNM stage | Method | First EGFR-TKI | Response | First ALK-TKI | Response |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kuo et al., 2010 | 2010 | 1 | 72 | F | Asian | No | AC | IV | Single | Gefitinib | PR PFS, 7.7 m | ND | - |
| Tiseo et al., 2011 | 2010 | 1 | 48 | M | White | No | SC/AC | NR | Single | Erlotinib | PD | ND | - |
| Popat et al., 2011 | 2011 | 1 | 65 | F | White | No | AC | IIIA | Single | Erlotinib | CR PFS, 25 m | ND | - |
| Tanaka et al., 2012 | 2012 | 1 | 39 | M | Asian | Yes | AC | IV | Single | Erlotinib | PD | ND | - |
| Santelmo et al., 2013 | 2013 | 1 | 52 | F | White | Yes | AC | IIIA | Single | Gefitinib | SD PFS, 7 m | ND | - |
| Chen et al. (2013) | 2013 | 1 | 56 | M | Asian | Yes | AC | IV | Single | Erlotinib | SD PFS, 8 m | Crizotinib | CR PFS, >22 m |
| Miyanaga et al., 2013 | 2013 | 1 | 55 | F | Asian | No | AC | IV | Single | Gefitinib | PD | NR | SD PFS, 4 m |
| Zhao et al. (2015) | 2014 | 1 | 48 | F | Asian | No | AC | IV | Single | Erlotinib | SD PFS, 5.3 m | Crizotinib | SD PFS, 3.5 m |
| Zhou et al. (2015) | 2014 | 1 | 47 | F | Asian | No | AC | IV | Single | Gefitinib | PD | ND | - |
| Chiari et al. (2014) | 2014 | 1 | 67 | F | White | No | AC | IV | Single | Gefitinib | PR PFS, 24 m | Crizotinib | PR PFS, 25 m |
| Yang et al., 2014 | 2014 | 13 | Median age, 59 | M, 5 F, 8 | Asian | No, 12 Yes, 1 | AC | IIIA, 2 IV, 11 | Single | Gefitinib, 3 Erlotinib, 5 Afatinib, 2 | 3 PR 4 PR, 1 PD 1 PR, 1 SD Median PFS 11.2 m | Crizotinib, 4 | 2 PR, 1 SD, 1 PD |
| Won et al. (2015) | 2014 | 14 | Median age, 55.5 | M, 6 F, 8 | Asian | No, 12 Yes, 2 | 13 AC 1 NR | IA, 1 IB, 1 IV, 11 | Single | Gefitinib, 3 | 1 SD, 2 PD | Crizotinib, 8 | 7 PR, 1SD |
| Xu et al., 2015 | 2015 | 1 | 71 | F | Asian | No | AC | IV | Single | Gefitinib | SD PFS, 8 m | ND | - |
| Ulivi et al., 2016 | 2015 | 6 | Median age, 61 | M, 1 F, 5 | White | No, 3 Yes, 3 | AC | NR | Single | Gefitinib, 5 Erlotinib, 1 | 1 CR, 2 PR, 2 PD 1 PR | ND | - |
| Schmid et al. (2017) | 2016 | 5 | Median age, 60 | M, 2 F, 3 | White | No, 3 Yes, 2 | AC | IVA, 1 IVB, 4 | Single,4 Dual, 1 | Afatinib, \ Osimertinib, \ Erlotinib, \ (n = 4) | 3 ORR, 1 SD Median PFS, 5.8 m | Alectinib, 1 Crizotinib, 2 | 1 PR 1 PR, 1 SD Median PFS, 5.7 m |
| Mao and Wu, (2017) | 2017 | 10 | Median age, 55.5 | M, 4 F, 6 | Asian | No, 9 Yes, 1 | AC | IV | Single | Erlotinib, \ Gefitinib, \ Icotinib, \ (n = 10) | 5 PR, 3 SD, 2 PD | Crizotinib, 5 | 3 PR, 1 SD, 1 PD |
| Shin et al., 2019 | 2019 | 3 | Median age, 57 | M, 1 F, 2 | Asian | No | AC | IV | Single | Gefitinib, 1 Osimertinib, 2 | 1 PR 1 PR; 1 PD | Crizotinib, 2 | 2 PD |
| Lu et al., 2021 | 2021 | 1 | 72 | M | Asian | No | AC | IIB | Single | Afatinib | PR PFS, 25 m | ND | - |
UK: unknown.
NA: not applicable.
ND: not done.